Search

Your search keyword '"Popat, Sanjay"' showing total 163 results

Search Constraints

Start Over You searched for: Author "Popat, Sanjay" Remove constraint Author: "Popat, Sanjay" Publisher elsevier bv Remove constraint Publisher: elsevier bv
163 results on '"Popat, Sanjay"'

Search Results

1. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

2. 119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study

3. NTRK gene fusion testing and management in lung cancer

4. 19 Utility of blood tests after completion of maintenance durvalumab after radical chemo-radiotherapy in patients with Non Small Cell Lung Cancer stage III

5. 48 Real world outcomes of a lung cancer genomic tumour advisory board: a single-centre experience in the United Kingdom

6. 7 Concordance of MET amplification detection between FISH and NGS in NSCLC

7. 81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery

8. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective

9. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe

10. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

11. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

12. A tailored approach to horizon scanning for cancer medicines

14. MesoGraph: Automatic profiling of mesothelioma subtypes from histological images

15. Malignant Mesothelioma subtyping via sampling driven multiple instance prediction on tissue image and cell morphology data

17. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial

20. Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

21. Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer

22. The spectrum of MET exon 14 skipping alterations in a UK population

23. A population-adjusted indirect treatment comparison of efficacy and safety of aumolertinib vs osimertinib in EGFR-mutated non-small cell lung cancer

24. Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting

25. Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study

26. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

27. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

29. A tailored approach to horizon scanning for cancer medicines

30. MARS 2: Extended Pleurectomy Decortication and Chemotherapy for Pleural Mesothelioma

31. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

32. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

34. Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

36. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients

38. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial

40. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

41. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

43. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

44. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

46. Reducing fixation time significantly reduces failure rates: an audit of failure rates and turn-around times on next generation sequencing (NGS) of non-small lung carcinomas

47. A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer

48. Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 study

49. Brigatinib vs crizotinib in ALK TKI-naive ALK+ NSCLC: final results from ALTA-1L

50. HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours

Catalog

Books, media, physical & digital resources